- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
62 result(s) found for: Disseminated cancer.
Displaying page 1 of 4.
EudraCT Number: 2016-000758-37 | Sponsor Protocol Number: NO18517 | Start Date*: 2016-08-23 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche AG | ||||||||||||||||||
Full Title: A Phase I Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children with Newly Diagnosed Brainstem Gliomas and High Grade Gliomas | ||||||||||||||||||
Medical condition: High Grade Glioma Brainstem Glioma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004529-22 | Sponsor Protocol Number: D3465C00001 | Start Date*: 2021-08-24 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Moderate-to-severe Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) BG (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001039-11 | Sponsor Protocol Number: GA30044 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) ES (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001270-33 | Sponsor Protocol Number: GCTSK003 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:Národný onkologický ústav | |||||||||||||
Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel... | |||||||||||||
Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-005038-39 | Sponsor Protocol Number: | Start Date*: 2020-12-02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: ChariotMS – A national (UK), multi-centre, randomised, double-blind, placebo-controlled (1:1) phase IIb efficacy trial with cost-utility analysis of cladribine tablets (3.5mg/kg over two years) in ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Advanced Multiple Sclerosis (EDSS 6.5-8.5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002667-34 | Sponsor Protocol Number: WA39085 | Start Date*: 2020-03-06 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLE... | ||||||||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023103-94 | Sponsor Protocol Number: 002:CD40L | Start Date*: 2011-07-04 |
Sponsor Name:Uppsala University | ||
Full Title: PHASE I/IIa AdCD40L IMMUNOGENE THERAPY FOR MALIGNANT MELANOMA PATIENTS WITH DISSEMINATED DISEASE | ||
Medical condition: malignant melanoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002665-35 | Sponsor Protocol Number: 190619 | Start Date*: 2019-10-14 | |||||||||||
Sponsor Name:Mikkel Holm Vendelbo | |||||||||||||
Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001948-21 | Sponsor Protocol Number: GETHI-2011-03 | Start Date*: 2012-08-17 | |||||||||||
Sponsor Name:Grupo Español de Tumores Huérfanos e Infrecuentes | |||||||||||||
Full Title: Open Phase II Study of Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary. GreKo Study. | |||||||||||||
Medical condition: Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023396-25 | Sponsor Protocol Number: SM101-201-sle-10 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:SuppreMol GmbH | |||||||||||||
Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005760-57 | Sponsor Protocol Number: CA42750 | Start Date*: 2021-08-27 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014446-28 | Sponsor Protocol Number: JANUS | Start Date*: 2009-12-03 | |||||||||||
Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO | |||||||||||||
Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER | |||||||||||||
Medical condition: invasive prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001392-21 | Sponsor Protocol Number: P018.087 | Start Date*: 2018-09-25 | |||||||||||||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||||||||||||
Full Title: A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythematosus | |||||||||||||||||||||||
Medical condition: systemic lupus erythematosus | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024111-13 | Sponsor Protocol Number: AIO-STO-0110 | Start Date*: 2011-04-15 | |||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||
Full Title: Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy | |||||||||||||||||||||||
Medical condition: Gastric adenocarcinoma and carcinoma of the esophago-gastric junction (type II and type III according to Siewert’s classification) prior to gastrectomy, with peritoneal carcinomatosis. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000882-34 | Sponsor Protocol Number: AGO/2014/002 | Start Date*: 2014-06-03 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Catheter based adjuvant intraperitoneal chemotherapy for carcinomatosis. | |||||||||||||
Medical condition: carcinomatosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005345-50 | Sponsor Protocol Number: RD-FCH-2014 | Start Date*: 2015-04-21 | |||||||||||
Sponsor Name:Masarykův onkologický ústav | |||||||||||||
Full Title: Diagnostic feasibility and morfological and functional correlation of PET examination in use of [18F]-Fluorocholin inj. in patients with prostate cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-006068-99 | Sponsor Protocol Number: DuoNen2020 | Start Date*: 2021-09-20 |
Sponsor Name:Narodowe Centrum Badań Jądrowych, Ośrodek Radioizotopów POLATOM | ||
Full Title: Tandem therapy LutaPol/ItraPol (177Lu / 90Y-DOTATATE) as an effective method in the treatment of neuroendocrine neoplasms, Acronym: DuoNen, 2019 / ABM / 01/00077 | ||
Medical condition: Diagnosed and confirmed histopathologically disseminated or locally unresectable, well and moderately differentiated (G1 and G2) neuroendocrine neoplasms of the gastrointestinal tract (GEP-NET) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005306-11 | Sponsor Protocol Number: SleepRCT_270215 | Start Date*: 2016-06-09 |
Sponsor Name:St. Olavs Hospital, trondheim University Hospital | ||
Full Title: Pharmacological treatment of insomnia in palliative care A randomized, double-blind, placebo controlled, parallel-group, multicenter trial investigating the short time effectiveness of zopiclone... | ||
Medical condition: The overall aim of this clinical trial is to improve the knowledge of the pharmacological treatment of insomnia in patients with advanced cancer who use opioids. Despite the high prevalence of inso... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001393-19 | Sponsor Protocol Number: 003:TCELL | Start Date*: 2014-04-08 |
Sponsor Name:Uppsala university | ||
Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial. | ||
Medical condition: CD19+ B cell lymphoma or leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000353-39 | Sponsor Protocol Number: CONFRONT | Start Date*: 2018-05-02 | ||||||||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST | ||||||||||||||||||
Full Title: The CONFRONT Phase I – II Trial: ACtivatiON oF immune RespONse in paTients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide i... | ||||||||||||||||||
Medical condition: R-M Head and Neck Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
